RT Journal Article
SR Electronic
T1 Proteomics identifies a type I IFN, prothrombotic hyperinflammatory circulating COVID-19 neutrophil signature distinct from non-COVID-19 ARDS
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.15.20195305
DO 10.1101/2020.09.15.20195305
A1 Leila Reyes
A1 Manuel A. Sanchez-Garcia
A1 Tyler Morrison
A1 Andrew J.M. Howden
A1 Emily R. Watts
A1 Simone Arienti
A1 Pranvera Sadiku
A1 Patricia Coelho
A1 Ananda S Mirchandani
A1 David Hope
A1 Sarah K. Clark
A1 Jo Singleton
A1 Shonna Johnston
A1 Robert Grecian
A1 Azin Poon
A1 Sarah Mcnamara
A1 Isla Harper
A1 Max Head Fourman
A1 Alejandro J. Brenes
A1 Shalini Pathak
A1 Amy Lloyd
A1 Gio Rodriguez Blanco
A1 Alex von Kriegsheim
A1 Bart Ghesquiere
A1 Wesley Vermaelen
A1 Camila T. Cologna
A1 Kevin Dhaliwal
A1 Nik Hirani
A1 David Dockrell
A1 Moira K. Whyte
A1 David Griffith
A1 Doreen A. Cantrell
A1 Sarah R. Walmsley
YR 2020
UL http://medrxiv.org/content/early/2020/09/18/2020.09.15.20195305.abstract
AB Understanding the mechanisms by which infection with SARS-CoV-2 leads to acute respiratory distress syndrome (ARDS) is of significant clinical interest given the mortality associated with severe and critical coronavirus induced disease 2019 (COVID-19). Neutrophils play a key role in the lung injury characteristic of non-COVID-19 ARDS, but a relative paucity of these cells is observed at post-mortem in lung tissue of patients who succumb to infection with SARS-CoV-2. With emerging evidence of a dysregulated innate immune response in COVID-19, we undertook a functional proteomic survey of circulating neutrophil populations, comparing patients with COVID-19 ARDS, non-COVID-19 ARDS, moderate COVID-19, and healthy controls. We observe that expansion of the circulating neutrophil compartment and the presence of activated low and normal density mature and immature neutrophil populations occurs in both COVID-19 and non-COVID-19 ARDS. In contrast, release of neutrophil granule proteins, neutrophil activation of the clotting cascade and formation of neutrophil platelet aggregates is significantly increased in COVID-19 ARDS. Importantly, activation of components of the neutrophil type I IFN responses is specific to infection with SARS-CoV-2 and linked to metabolic rewiring. Together this work highlights how differential activation of circulating neutrophil populations may contribute to the pathogenesis of ARDS, identifying processes that are specific to COVID-19 ARDS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by a Wellcome Trust Senior Clinical Fellowship award (209220) and a CRUK cancer immunology project award (C62207/A24495) to S.R.W, Wellcome Clinical training Fellowship awards to T.M. (214383/Z/18/Z) and E.R.W (108717/Z/15/Z), a Wellcome Trust Post-doctoral Training Clinical Fellowship awarded to A.S.M (110086), a Medical Research Foundation PhD Studentship to S.A., UKRI/NIHR funding through the UK Coronavirus Immunology Consortium (UK-CIC) and a CSO grant (COV/DUN/20/01) to D.A.C, and a LifeArc STOPCOVID award to A.P and S.M.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human peripheral venous blood was taken from healthy volunteers with written informed consent obtained from all participants prior to sample collection as approved by the University of Edinburgh Centre for Inflammation Research Blood Resource Management Committee (AMREC 15-HV-013). The collection of peripheral venous blood from male or female patients diagnosed with COVID-19 and/or presenting with ARDS was approved by Scotland A Research Ethics Committee. Patient recruitment took place from April 2020 through August 2020 from The Royal Infirmary of Edinburgh, Scotland, UK through the ARDS Neut (20/SS/0002) and CASCADE (20/SS/0052) Study, with informed consent obtained by proxy.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes